GSK Hits Consumer Brand Divestment Target As Q3 Performance Mixed
GSK's Brian McNamara says the firm has hit its £1bn brand divestment target which will help fund the restructuring of its Consumer Healthcare business before it is spun off in 2022.
You may also be interested in...
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.
With the European Commission "carefully assessing" the judgment of Europe's highest court that CBD is not a narcotic, HBW Insight speaks to an expert in cannabis law about what is likely to happen next.